State Ledger
Company profile

Transcode Therapeutics, Inc. CIK 1829635

Ticker
RNAZ (Nasdaq)
Industry
Pharmaceutical Preparations
Headquarters
Boston, MA 02109
Fiscal year end
2025 (FY)
Market Data
Close
$1.95
Change
+$0.18
Change %
9.86%
Volume
1,720

RNAZ · trading date Oct 9, 2026 · previous close $1.78 · source: Alpaca (IEX feed, not consolidated full-market data).

Key Financials
Revenue
—
Net income
-$34.66M
Total assets
$162.40M
Total liabilities
$10.52M
Stockholders' equity
$10.34M
Cash & equivalents
$17.81M
Operating income
-$27.98M
Operating cash flow
-$19.52M
Capital expenditures
$6.7K

Fiscal year 2025, via 10-K filed 2026-04-15. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.

Financial Performance
Operating margin
—
Net margin
—
Free cash flow
-$19.52M
Free cash flow margin
—
Liabilities / assets
6.5%
Equity / assets
6.4%
CapEx / revenue
—
Operating cash flow / net income
0.56×

Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.

Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025 — -$34.66M $162.40M $10.52M $10.34M
2024 — -$16.75M $7.29M $9.31M -$2.02M
2023 — -$18.55M $5.17M $3.53M $1.64M
2022 — -$17.56M $7.59M $4.35M $3.24M
2021 — -$6.84M $22.94M $2.53M $20.40M
Company Details
SIC code
2834
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 4
2026-09-11
Financials filed via
Form 10-K
filed 2026-04-15

"Most recent SEC filing" may differ from the filing used for the financial figures above.

Location
Boston, MA 02109
6 LIBERTY SQUARE
Data & Methodology

SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:35 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.

← Back to Massachusetts — Public Companies